BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24491504)

  • 1. Ensemble docking and molecular dynamics identify knoevenagel curcumin derivatives with potent anti-EGFR activity.
    Yadav IS; Nandekar PP; Srivastavaa S; Sangamwar A; Chaudhury A; Agarwal SM
    Gene; 2014 Apr; 539(1):82-90. PubMed ID: 24491504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and molecular docking of α,β-unsaturated cyclohexanone analogous of curcumin as potent EGFR inhibitors with antiproliferative activity.
    Xu YY; Cao Y; Ma H; Li HQ; Ao GZ
    Bioorg Med Chem; 2013 Jan; 21(2):388-94. PubMed ID: 23245570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
    Ghosh S; Narla RK; Zheng Y; Liu XP; Jun X; Mao C; Sudbeck EA; Uckun FM
    Anticancer Drug Des; 1999 Oct; 14(5):403-10. PubMed ID: 10766295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
    Li Y; Tan C; Gao C; Zhang C; Luan X; Chen X; Liu H; Chen Y; Jiang Y
    Bioorg Med Chem; 2011 Aug; 19(15):4529-35. PubMed ID: 21724404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational analyses of curcuminoid analogs against kinase domain of HER2.
    Yim-im W; Sawatdichaikul O; Semsri S; Horata N; Mokmak W; Tongsima S; Suksamrarn A; Choowongkomon K
    BMC Bioinformatics; 2014 Aug; 15(1):261. PubMed ID: 25089037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors.
    Gupta AK; Bhunia SS; Balaramnavar VM; Saxena AK
    SAR QSAR Environ Res; 2011 Jun; 22(3):239-63. PubMed ID: 21400356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computer-aided identification of EGFR tyrosine kinase inhibitors using ginsenosides from Panax ginseng.
    Sathishkumar N; Karpagam V; Sathiyamoorthy S; Woo MJ; Kim YJ; Yang DC
    Comput Biol Med; 2013 Jul; 43(6):786-97. PubMed ID: 23668355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-ones as novel EGFR inhibitor by scaffold hopping.
    Kang BR; Shan AL; Li YP; Xu J; Lu SM; Zhang SQ
    Bioorg Med Chem; 2013 Nov; 21(22):6956-64. PubMed ID: 24094432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures.
    Sato T; Watanabe H; Tsuganezawa K; Yuki H; Mikuni J; Yoshikawa S; Kukimoto-Niino M; Fujimoto T; Terazawa Y; Wakiyama M; Kojima H; Okabe T; Nagano T; Shirouzu M; Yokoyama S; Tanaka A; Honma T
    Bioorg Med Chem; 2012 Jun; 20(12):3756-67. PubMed ID: 22607878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
    Xu YY; Li SN; Yu GJ; Hu QH; Li HQ
    Bioorg Med Chem; 2013 Oct; 21(19):6084-91. PubMed ID: 23962660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines.
    Hamed MM; Abou El Ella DA; Keeton AB; Piazza GA; Abadi AH; Hartmann RW; Engel M
    ChemMedChem; 2013 Sep; 8(9):1495-504. PubMed ID: 23847159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies.
    Yuan M; Luo M; Song Y; Xu Q; Wang X; Cao Y; Bu X; Ren Y; Hu X
    Bioorg Med Chem; 2011 Feb; 19(3):1189-96. PubMed ID: 21237663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells.
    Cavasotto CN; Ortiz MA; Abagyan RA; Piedrafita FJ
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1969-74. PubMed ID: 16413185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
    Ahmed M; Sadek MM; Abouzid KA; Wang F
    J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis.
    Sudha A; Srinivasan P; Rameshthangam P
    J Recept Signal Transduct Res; 2015 Apr; 35(2):137-48. PubMed ID: 25069678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
    Rao GW; Xu GJ; Wang J; Jiang XL; Li HB
    ChemMedChem; 2013 Jun; 8(6):928-33. PubMed ID: 23640754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
    Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
    Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
    Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating molecular dynamics-guided lead optimization of EGFR inhibitors.
    Lavecchia MJ; Puig de la Bellacasa R; Borrell JI; Cavasotto CN
    Bioorg Med Chem; 2016 Feb; 24(4):768-78. PubMed ID: 26810832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of quinazolinone tagged acridones as cytotoxic agents and their effects on EGFR tyrosine kinase.
    Babu YR; Bhagavanraju M; Reddy GD; Peters GJ; Prasad VV
    Arch Pharm (Weinheim); 2014 Sep; 347(9):624-34. PubMed ID: 24866341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.